Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment

Phase 2

Completed

Conditions: Inflammation of Mouth
Acute Mucous Inflammation

Interventions: Drug: Placebo
Drug: Anthocyanin

Registration Number: NCT02536781

Lead Sponsor: Khon Kaen University

Brief Summary: The purpose of this study is to compare the oral inflammatory reduction effect caused from orthodontic treatment of anthocyanin and placebo mouthrinse.

Detailed Description: Multiple inflammatory lesions caused from orthodontic treatments are commonly found in these patients and the irritations from the insertion of the orthodontic wire are hard to apply the topical cream or gel. Standard treatment to prevent oral mucosal irritation caused from orthodontic brackets and wires is an orthodontic wax to cover the appliances. However, the covering wax is just a prophylactic measure to protect the mucosal irritation. Thus, the patients still need a specific treatment for their oral inflammatory condition. Developing a product that can treat entire inflammatory areas in oral cavity, promote oral hygiene, and anti-fungal would be beneficial and useful for the orthodontic treatment. Anthocyanins, one of a natural compound from red, blue, purple vegetables, fruits, and flowers, have many beneficial effects including anti-inflammation and the most important effect superior to steroid usage is anti-candidiasis. Interesting in anthocyanins as the natural treatment, has drawn attention due to the benefits in oral inflammation. Previous study on the effect of a topical anthocyanin gel demonstrated positive effect of topical anthocyanins gel against oral inflammation in human subjects at 6 weeks. Unfortunately, anthocyanin is not stable and easily to be degraded. Therefore, stabilized anthocyanin oral formulation needs to be developed and the formulation needs to provide stable and active anthocyanins in suitable oral formula. This study aims to prepare and investigate effects of anthocyanin complex in order to formulate the mouthrinse for anti-inflammation caused by orthodontic treatment. Thus, to prepare and investigate the effects of anthocyanin activities after forming complexation in order to formulate the mouthrinse would be evaluated. In addition, the examination of anti-oral inflammation caused by orthodontic treatment by anthocyanin complex in clinical trial will be conducted.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 70

Inclusion Criteria

Male and/or females between the ages of 18 and 35 with oral inflammation, investigated by a dentist, caused by orthodontic devices.
The inflammatory lesions are occurred at labial and/or buccal mucosa.
Be able to communicate well with the investigator and to comply with the requirements of the entire study.
Not participate in other project(s).
Be willingness to give written informed consent (prior to any study-related procedures being performed) and to be able to adhere to the study restrictions and examination schedule.

Exclusion Criteria

- Have the persistent inflammatory lesions and/or ulcers that cannot be healed more than 2 weeks or the inflammation that may lead to be oral cancer.
Have severe oral inflammation or the inflammation occur from ongoing head and neck chemotherapy or serious oral inflammatory such as periodontitis and oral lichen planus.
Taking steroid or applying topical steroid within or 7 days before participated in this study.
Have a history of allergy or hypersensitivity to any red, blue, or purple color fruits and vegetables such as berry groups.
Patients with auto-immune diseases or diseases that related to wound healing process such as diabetes.
Patients that cannot meet the follow up or drop out of the experiments.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebol	Placebo	Placebo
Anthocynin	Anthocyanin	Anthocyanin

Primary Outcome Measures

Name	Time	Method
Wound Size (mm^2) Reduction	Days 0 and 7 after treatment	Comparing between the active and placebo about the wound size reduction from day 0 to day 7 after treatment

Secondary Outcome Measures